Papers - Nakajima, Shinichiro

Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study

Nagata T., Shinagawa S., Nakajima S., Mimura M., Shigeta M.

Journal of Alzheimer's disease : JAD (Journal of Alzheimer's disease : JAD)  66 ( 1 ) 139 - 148 2018

　View Summary

BACKGROUND/OBJECTIVE: To assess associations between improvements in neuropsychiatric symptoms (NPS) and neurocognitive change in patients with Alzheimer's disease (AD) during treatment using the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer Disease (CATIE-AD) dataset. METHODS: AD outpatients with NPS who needed pharmacological treatment (n = 421) were followed up with antipsychotics, citalopram, or placebo for up to 36 weeks (mean±SD = 252±52 days). The study aim was to investigate associations between improvement in each NPS evaluating scale (by Clinical Global Impression of Change [CGI-C], Neuropsychiatric Inventory [NPI], or Brief Psychiatric Scale [BPRS]) at endpoint (week 36 or early termination [ET], n = 340) and neurocognitive change (change score in the Mini-Mental State Examination [MMSE] between endpoint and baseline during the treatment). Multiple logistic regression analyses were performed on the associations between each NPS improvement and neurocognitive change as well as socio-clinico-demographic variables of interest. RESULTS: At endpoint, NPS improvement rates were 76.1%, 70.8%, and 58.1% in CGI-C, NPI, and BPRS, respectively, while MMSE score change was -2.3±3.8. NPS improvement was significantly related to more severe psychotic symptoms at baseline and preserved levels of neurocognition (smaller MMSE score change) among several variables. CONCLUSIONS: Our findings suggested that neurocognitive preservation may be associated with attaining optimal benefits from any treatment against NPSs in a longitudinal treatment course of patients with AD.

• Access to Document (DOI)

Baseline predictors of antipsychotic treatment continuation and response at week 8 in patients with Alzheimer’s disease with psychosis or aggressive symptoms: an analysis of the CATIE-AD Study

Nagata T, Nakajima S, Shinagawa S, Plitman E, Nakayama K, Graff-Guerrero A, Mimura M.

 2017

The effects of cortical hypometabolism and hippocampal atrophy on clinical trajectories in mild cognitive impairment with suspected non-Alzheimer's pathology: A brief report.

Chung J, Plitman E, Nakajima S, Shinagawa S, Iwata Y, Gerretsen P, Kim J, Patel R, Chakravarty M, Caravaggio F, Graff-Guerrero A.

J Alzheimers Dis.  2017

Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning.

Caravaggio F, Gerretsen P, Mar W, Chung JK, Plitman E, Nakajima S, Kim J, Iwata Y, Patel R, Chakravarty MM, Remington G, Graff-Guerrero A, Menon M.

Psychoneuroendocrinology  2017

Corticotropin-releasing hormone and dopamine release in healthy individuals.

Payer D, Williams B, Mansouri E, Stevanovski S, Nakajima S, Le Foll B, Kish S, Houle S, Mizrahi R, George SR, George TP, Boileau I.

Psychoneuroendocrinology  2017

Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Plitman E, Iwata Y, Caravaggio F1, Nakajima S, Chung JK, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G, Graff-Guerrero A.

Schizophr Bull  2017

Investigating the effects of norepinephrine α1 receptor blockade on dopamine levels: A pilot PET study with [11 C]-(+)-PHNO in controls.

Le Foll B, Thiruchselvam T, Lu SX, Mohammed S, Mansouri E, Lagzdins D, Nakajima S, Wilson AA, Graff-Guerrero A, Di Ciano P, Boileau I.

Synapse  2017

Impaired illness awareness and leftward visuospatial inattention in schizophrenia are attributable to a common neural deficit - Posterior parietal hemispheric imbalance.

Kim J1, Plitman E1, Nakajima S2, Chung JK1, Alshehri Y3, Iwata Y, Caravaggio F, Pollock BG, Pothier D, Graff-Guerrero A, Gerretsen P.

Med Hypotheses  2017

Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.

Chung JK, Plitman E, Nakajima S, Caravaggio F, Iwata Y, Gerretsen P, Kim J, Takeuchi H, Shinagawa S, Patel R, Chakravarty MM, Graff-Guerrero A; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis.  2017

Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology.

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU.

American Journal of Psychiatry  2017

Impaired Illness Awareness as a Predictor of Conversion from MCI to AD and a Function of Reduced Brain Metabolism: An ADNI study.

Gerretsen P, Chung J, Parita Shah, Plitman E, Iwata Y, Nakajima S, Graff-Guerrero A.

J Clin Psychiatry  2017

Benzodiazepine Use Attenuates Cortical β-Amyloid and is Not Associated with Progressive Cognitive Decline in Nondemented Elderly Adults: A Pilot Study Using F18-Florbetapir Positron Emission Tomography.

Chung JK, Nakajima S, Shinagawa S, Plitman E, Chakravarty MM, Iwata Y, Caravaggio F, Pollock BG, Gerretsen P, Graff-Guerrero A; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry.  2016

Cortical Amyloid Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment

Chung JK, Plitman E, Nakajima S, Chakravarty MM, Caravaggio F, Gerretsen P, Iwata Y, Graff-Guerrero A; Alzheimer’s Disease Neuroimaging Initiative.

J Geriatr Psychiatry Neurol.  2016

Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.

Fervaha G, Caravaggio F, Mamo DC, Mulsant BH, Pollock BG, Nakajima S, Gerretsen P, Rajji TK, Mar W, Iwata Y, Plitman E, Chung JK, Remington G, Graff-Guerrero A

Psychopharmacology (Berl).  2016

Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Chung JK, Nakajima S, Plitman E, Iwata Y, Uy D, Gerretsen P, Caravaggio F, Chakravarty MM, Graff-Guerrero A.

Am J Geriatr Psychiatry.  2016

Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO.

Caravaggio F, Chung JK, Gerretsen P, Fervaha G, Nakajima S, Plitman E, Iwata Y, Wilson A, Graff-Guerrero A

Soc Neurosci.  2016

Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.

Nagata T, Shinagawa S, Nakajima S, Plitman E, Mihashi Y, Hayashi S, Mimura M, Nakayama K.

J Alzheimers Dis.  2016

Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment.

Chung JK, Plitman E, Nakajima S, Chakravarty MM, Caravaggio F, Takeuchi H, Gerretsen P, Iwata Y, Patel R, Mulsant BH, Graff-Guerrero A.

J Alzheimers Dis.  2016

Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated With Mirtazapine.

Funaki K, Nakajima S, Suzuki T, Mimura M, Uchida H.

J Clin Pharmacol.  2016

Exploring personality traits related to dopamine D2/3 receptor availability in striatal subregions of humans.

Caravaggio F, Fervaha G, Chung JK, Gerretsen P, Nakajima S, Plitman E, Iwata Y, Wilson A, Graff-Guerrero A.

Eur Neuropsychopharmacol.  2016